Compare COLL & PHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COLL | PHR |
|---|---|---|
| Founded | 2002 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.2B |
| IPO Year | 2015 | 2019 |
| Metric | COLL | PHR |
|---|---|---|
| Price | $49.40 | $16.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 17 |
| Target Price | ★ $47.50 | $31.76 |
| AVG Volume (30 Days) | 531.1K | ★ 1.9M |
| Earning Date | 11-06-2025 | 12-08-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.63 | N/A |
| Revenue | ★ $757,067,000.00 | $463,205,000.00 |
| Revenue This Year | $26.35 | $14.91 |
| Revenue Next Year | $3.67 | $12.07 |
| P/E Ratio | $30.08 | ★ N/A |
| Revenue Growth | ★ 26.34 | 14.33 |
| 52 Week Low | $23.23 | $15.41 |
| 52 Week High | $49.49 | $32.76 |
| Indicator | COLL | PHR |
|---|---|---|
| Relative Strength Index (RSI) | 71.50 | 30.83 |
| Support Level | $47.83 | $15.97 |
| Resistance Level | $49.49 | $16.90 |
| Average True Range (ATR) | 1.34 | 1.00 |
| MACD | -0.19 | -0.17 |
| Stochastic Oscillator | 87.20 | 17.32 |
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
Phreesia Inc is a provider of comprehensive software solutions that improve the operational and financial performance of healthcare organizations by activating patients in their care to optimize patient health outcomes. Through its SaaS-based technology platform, it offers healthcare services clients a robust suite of integrated solutions that manage patient access, registration, payments, and clinical support. The Phreesia Platform encompasses a comprehensive range of technologies and services, including, initial patient contact, registration, automated answering services, appointment scheduling, payments, and post-appointment patient surveys.